Phase 3
Completed N=2,238
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
Source: ClinicalTrials.gov NCT01974323 ↗Enrolled (actual)
2,238
Serious AEs
0.4%
Results posted
Feb 2017
Primary outcomePrimary: Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) — 29.8; 20.9 Percentage of Patients
◆ Published Evidence
Emerging
17citations · ~2 / year
Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials.
Summary
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
Linked Publications (4)
-
Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials.
-
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
-
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
-
Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) |
29.8; 20.9 | — |
| PRIMARY Change From Baseline in Inflammatory Facial Lesion Counts |
29.6; 30.0; -15.6; -14.0 | — |
| PRIMARY Change From Baseline in Noninflammatory Facial Lesion Counts |
46.7; 46.7; -20.8; -18.7 | — |
| SECONDARY Change From Baseline in Total Lesion Counts |
76.4; 76.9; -36.2; -32.3 | — |
| SECONDARY Percentage Change From Baseline in Total Lesion Counts |
-48.9; -43.2 | — |
| SECONDARY Percentage of Patients Reporting "Very Good" or "Excellent" on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS) |
24.2; 22.0 | — |
| SECONDARY Change From Baseline in the 9-Item ASIS Sign Domain Score |
2.04; 2.07; -0.74; -0.68 | — |
| SECONDARY Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale |
48.5; 49.3 | — |
| SECONDARY Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale |
53.8; 52.9 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of acne vulgaris
- Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight, tanning beds) throughout the study
Exclusion Criteria
- Severe cystic acne, acne conglobata, acne fulminans, or secondary acne
- Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling, comedo extraction) in the past week
- Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]), retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks
- Use of birth control pills strictly for acne control
Data sourced from ClinicalTrials.gov (NCT01974323) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.